Timothy J Price1,2, Carol Beeke3, Amanda Rose Townsend4,5, Louisa Lo4, Roy Amitesh6, Robert Padbury3, David Roder7, Guy Maddern8, James Moore9, Christos Karapetis6,10. 1. Department of Medical Oncology, The Queen Elizabeth Hospital, Woodville Road, Woodville, SA, 5011, Australia. timothy.price@health.sa.gov.au. 2. School of Medicine, University of Adelaide, Adelaide, SA, Australia. timothy.price@health.sa.gov.au. 3. Department of Surgery, Flinders Medical Centre, Adelaide, SA, Australia. 4. Department of Medical Oncology, The Queen Elizabeth Hospital, Woodville Road, Woodville, SA, 5011, Australia. 5. School of Medicine, University of Adelaide, Adelaide, SA, Australia. 6. Department of Medical Oncology, Flinders Medical Centre, Adelaide, SA, Australia. 7. School of Population Health, University of South Australia, Adelaide, SA, Australia. 8. Department of Surgery, The Queen Elizabeth Hospital, Adelaide, SA, Australia. 9. Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, Australia. 10. Flinders University, Flinders Centre for Innovation in Cancer, Adelaide, SA, Australia.
Abstract
BACKGROUND: Patients with metastatic colorectal cancer (mCRC) with BRAF mutation (BRAF MT) generally have a poorer prognosis. BRAF MT may also have implications for treatment strategy. Despite this, inclusion of BRAF in routine molecular testing varies. Here we report the frequency of BRAF reporting in the South Australian (SA) mCRC registry reflecting community practice, together with the survival outcomes based on mutation status. METHODS: The SA population-based mCRC registry was analysed to assess the number of patients where a BRAF MT result was available. The patient characteristics are reported and overall survival was analysed using the Kaplan-Meier method. RESULTS: Of the 3639 patients who have been entered in the registry, only 6.2% (227) have BRAF MT results available. Of the patients tested, the BRAF MT rate is 12.7%. The mutation rate was highest in rightsided primary; right colon 23 versus left colon 8.9% and rectum 7%. There was no significant difference in median age or male/female proportion. The median overall survival (mOS) for BRAF MT versus wild-type (WT) patients is 14.0 versus 32.9 months (p = 0.003). For patients who have chemotherapy (plus or minus surgery) the mOS is 14.6 months BRAF MT versus 36.1 months (p ≤ 0.001) WT. Liver or lung resection was performed on only 8% of the BRAF MT group versus 26.5% of the WT group. CONCLUSION: Results in a population setting confirm our understanding that BRAF MT is more frequently right sided and of lower frequency in rectal cancer. Survival is lower for patients with mCRC that have BRAF MT, regardless of the therapy. BRAF testing is currently performed infrequently in an Australian setting despite its importance as a significant prognostic factor, and the implications for alternate therapeutic approaches.
BACKGROUND:Patients with metastatic colorectal cancer (mCRC) with BRAF mutation (BRAF MT) generally have a poorer prognosis. BRAF MT may also have implications for treatment strategy. Despite this, inclusion of BRAF in routine molecular testing varies. Here we report the frequency of BRAF reporting in the South Australian (SA) mCRC registry reflecting community practice, together with the survival outcomes based on mutation status. METHODS: The SA population-based mCRC registry was analysed to assess the number of patients where a BRAF MT result was available. The patient characteristics are reported and overall survival was analysed using the Kaplan-Meier method. RESULTS: Of the 3639 patients who have been entered in the registry, only 6.2% (227) have BRAF MT results available. Of the patients tested, the BRAF MT rate is 12.7%. The mutation rate was highest in rightsided primary; right colon 23 versus left colon 8.9% and rectum 7%. There was no significant difference in median age or male/female proportion. The median overall survival (mOS) for BRAF MT versus wild-type (WT) patients is 14.0 versus 32.9 months (p = 0.003). For patients who have chemotherapy (plus or minus surgery) the mOS is 14.6 months BRAF MT versus 36.1 months (p ≤ 0.001) WT. Liver or lung resection was performed on only 8% of the BRAF MT group versus 26.5% of the WT group. CONCLUSION: Results in a population setting confirm our understanding that BRAF MT is more frequently right sided and of lower frequency in rectal cancer. Survival is lower for patients with mCRC that have BRAF MT, regardless of the therapy. BRAF testing is currently performed infrequently in an Australian setting despite its importance as a significant prognostic factor, and the implications for alternate therapeutic approaches.
Authors: Van Morris; Michael J Overman; Zhi-Qin Jiang; Christopher Garrett; Shweta Agarwal; Cathy Eng; Bryan Kee; David Fogelman; Arvind Dasari; Robert Wolff; Dipen Maru; Scott Kopetz Journal: Clin Colorectal Cancer Date: 2014-06-23 Impact factor: 4.481
Authors: C Bokemeyer; I Bondarenko; J T Hartmann; F de Braud; G Schuch; A Zubel; I Celik; M Schlichting; P Koralewski Journal: Ann Oncol Date: 2011-01-12 Impact factor: 32.976
Authors: Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman Journal: Cancer Discov Date: 2012-01-16 Impact factor: 39.397
Authors: Timothy J Price; Eva Segelov; Matthew Burge; Daniel G Haller; Niall C Tebbutt; Christos S Karapetis; Cornelis J A Punt; Nick Pavlakis; Dirk Arnold; Peter Gibbs; Jeremy D Shapiro Journal: Expert Rev Anticancer Ther Date: 2014-08-20 Impact factor: 4.512
Authors: Timothy J Price; Jennifer E Hardingham; Chee K Lee; Andrew Weickhardt; Amanda R Townsend; Joseph W Wrin; Ann Chua; Aravind Shivasami; Michelle M Cummins; Carmel Murone; Niall C Tebbutt Journal: J Clin Oncol Date: 2011-06-06 Impact factor: 44.544
Authors: Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello Journal: J Clin Oncol Date: 2011-04-18 Impact factor: 44.544
Authors: F Loupakis; C Cremolini; L Salvatore; G Masi; E Sensi; M Schirripa; A Michelucci; E Pfanner; I Brunetti; C Lupi; C Antoniotti; F Bergamo; S Lonardi; V Zagonel; P Simi; G Fontanini; A Falcone Journal: Eur J Cancer Date: 2013-10-15 Impact factor: 9.162
Authors: Lauren C Bylsma; Christina Gillezeau; Tamer A Garawin; Michael A Kelsh; Jon P Fryzek; Laura Sangaré; Kimberly A Lowe Journal: Cancer Med Date: 2019-12-19 Impact factor: 4.452